pharma · Generalized Myasthenia Gravis · Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
argenx
argenx is a pharma organization headquartered in GENT, BE. Primary therapeutic focus areas include Generalized Myasthenia Gravis, Chronic inflammatory demyelinating polyneuropathy (CIDP), Bullous Pemphigoid, Thyroid Eye
33 Arch Street, Suite 3201, Boston, MA 02110, US HQ
2008 Founded
2,179 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 33 Arch Street, Suite 3201, Boston, MA 02110, US
- Founded
- 2008
- Employees
- 2,179
- Programs
- 32
- Drugs
- 16
- Patents
- 0
EFG PH20 SC
Phase 3 · mab · Active Idiopathic Inflammatory Myopathy
EFG PH20 SC for Active Idiopathic Inflammatory Myopathy is a Phase 3 program (mab) at argenx with 1 ClinicalTrials.gov record(s).
Internal code ARGX-113-2007
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- argenx
- Phase
- Phase 3
- Modality
- mab
- Indication
- Active Idiopathic Inflammatory Myopathy
- Status
- active
- Trials
- 1